Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform. - Zhang Y; Li Z; Ritter J; Brea EJ; Mahadevan NR; Dillon DA; Park SR; Liu EM; Tolstorukov MY; McGourty WE; Lizotte P; Ivanova EV; et al. (Cell reports. Medicine, 2025)